Denali Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview

Denali Therapeutics

02/08/2024 14:23

* Denali Therapeutics Inc  DNLI.OQ   DNLI.O  is expected
to show a
rise in quarterly revenue when it reports  results  for the
period ending September 30 2024
    * The South San Francisco California-based  company is
expected to
report a 887.5% increase in revenue to $12.512 million from
$1.27 million a year ago, according to the mean estimate from 12
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Denali Therapeutics Inc
is for
a loss of 63 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 4.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Denali
Therapeutics Inc is $35.50​, above​ its last closing price
of $23.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.70       -0.69      -0.59     Beat    13.9
 Jan. 1 2024   -0.71       -0.70      -0.78     Missed  -11
 Jan. 1 0001   -0.79       -0.80      -0.86     Missed  -6.9​
 Jan. 1 0001   -0.78       -0.80      -0.72     Beat    10.3
 ​​Jan.        -0.60       -0.68      1.30      Beat    290.1
 1 0001                                                 
 Mar. 31 2023  -0.71       -0.70      -0.80     Missed  -13.6​
 Dec. 31 2022  -0.77       -0.79      -0.75     Beat    5.1
 Sep. 30 2022  -0.78       -0.81      -0.84     Missed  -4.2
 This summary was machine generated August 2 at 13:23 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)